Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
8.15
0.00 (0.00%)
Sep 6, 2024, 4:00 PM EDT - Market closed
Company Description
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.
The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.
The company was incorporated in 2015 and is based in Fort Worth, Texas.
Actuate Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Aug 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Daniel Schmitt |
Contact Details
Address: 1751 River Run, Suite 400 Fort Worth, Texas 76107 United States | |
| Phone | (817) 887-8455 |
| Website | actuatetherapeutics.com |
Stock Details
| Ticker Symbol | ACTU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001652935 |
| Employer ID | 47-3044785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel M. Schmitt | President, Chief Executive Officer and Director |
| Andrew P. Mazar, Ph.D. | Chief Operating Officer |
| Paul Lytle | Chief Financial Officer |
| Aaron G.L. Fletcher, Ph.D. | Chairperson and Director |
| Les Kreis, Jr. | Director |
| Todd Thomson | Director |
| Dan Zabrowski, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 19, 2024 | 8-K | Current Report |
| Aug 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 13, 2024 | POS EX | Filing |
| Aug 13, 2024 | 424B4 | Prospectus |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | CERT | Certification by an exchange approving securities for listing |
| Aug 12, 2024 | 8-A12B/A | Filing |
| Jul 23, 2024 | FWP | Free Writing Prospectus |